Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
J Clin Psychopharmacol ; 33(4): 453-62, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23764684

ABSTRACT

Women of childbearing age are often affected with psychotic disorders, requiring the use of antipsychotic medication during pregnancy. In the present study, we prospectively followed the pregnancies of 561 women exposed to second-generation antipsychotic agents (SGAs; study cohort) and compared these to 284 pregnant women exposed to first-generation antipsychotic agents (FGAs; comparison cohort I) and to 1122 pregnant women using drugs known as not harmful to the unborn (comparison cohort II). Subjects were enrolled through the Institute's consultation service. Major malformation rates of SGA exposed were higher compared to comparison cohort II (adjusted odds ratio, 2.17; 95% confidence interval, 1.20-3.91), possibly reflecting a detection bias concerning atrial and ventricular septal defects. Postnatal disorders occurred significantly more often in infants prenatally exposed to SGAs (15.6%) and FGAs (21.6%) compared to 4.2% of comparison cohort II. Cumulative incidences of elective terminations of pregnancy were significantly higher in both the study cohort (17%) and comparison cohort I (21%) compared to comparison cohort II (3%), whereas the rates of spontaneous abortions did not differ. The numbers of stillbirths and neonatal deaths were within the reference range. Preterm birth and low birth weight were more common in infants exposed to FGAs. To conclude, our findings did not reveal a major teratogenic risk for SGAs, making the better studied drugs of this group a treatment option during pregnancy. Because neonates exposed to SGAs or FGAs in the last gestational week are at higher risk of postnatal disorders, delivery should be planned in clinics with neonatal intensive care units.


Subject(s)
Antipsychotic Agents/therapeutic use , Pregnancy Complications/drug therapy , Psychotic Disorders/drug therapy , Abnormalities, Drug-Induced/etiology , Abnormalities, Drug-Induced/mortality , Abortion, Induced , Abortion, Spontaneous/chemically induced , Abortion, Spontaneous/mortality , Adult , Antipsychotic Agents/adverse effects , Antipsychotic Agents/classification , Case-Control Studies , Female , Gestational Age , Humans , Infant , Infant Mortality , Infant, Low Birth Weight , Infant, Newborn , Logistic Models , Odds Ratio , Pregnancy , Pregnancy Complications/diagnosis , Pregnancy Complications/psychology , Premature Birth , Prenatal Exposure Delayed Effects , Prospective Studies , Psychotic Disorders/diagnosis , Psychotic Disorders/psychology , Risk Assessment , Risk Factors , Stillbirth , Treatment Outcome
3.
Clin Orthop Relat Res ; 470(8): 2325-31, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22692823

ABSTRACT

BACKGROUND: Metal-on-metal bearings frequently are used in young patients leading to the concern that disseminated metals such as chromium (Cr) and cobalt (Co) as the main constituents could affect pregnancies. CASE DESCRIPTION: We describe a 41-year-old patient with bilateral metal-on-metal hip arthroplasties, a recurrent pseudotumor, and extremely high blood levels (Cr 39 µg/L, Co 138 µg/L) at 12 gestational weeks. At different gestational weeks, maternal blood, aspirate of the pseudotumor, and amniotic fluid were analyzed for Cr and Co. Therapy with chelating agents was not recommended because the mother showed no symptoms of toxicity and the safety of chelating therapy during pregnancy is not established. At 38 weeks of gestation, a healthy male infant was delivered with elevated Cr and Co cord blood levels. At the age of 8 weeks, the infant's Cr was comparable to the cord blood level, whereas the Co decreased considerably without treatment. At the age of 14 weeks, the infant's development was seemingly uneventful and no signs of toxicity were obvious. LITERATURE REVIEW: Carcinogenic, mutagenic, and teratogenic potentials of these metals have been suggested. However, we found no published clinical observations in context with pregnancies of women with hip arthroplasties using metal-on-metal implants. To our knowledge, this is the first report of such high levels of Cr and Co in a human pregnancy. PURPOSES AND CLINICAL RELEVANCE: Although we cannot generalize from one case, the seemingly uneventful outcome of this pregnancy may reassure colleagues when counseling patients with high ion levels whether to carry a pregnancy to term.


Subject(s)
Arthroplasty, Replacement, Hip , Chromium/blood , Cobalt/blood , Hip Prosthesis/adverse effects , Maternal Exposure , Pregnancy Complications, Hematologic/blood , Adult , Female , Fetal Blood/chemistry , Gestational Age , Humans , Infant, Newborn , Live Birth , Male , Maternal-Fetal Exchange , Pregnancy , Pregnancy Trimester, First , Prosthesis Design
4.
Vaccine ; 30(30): 4445-52, 2012 Jun 22.
Article in English | MEDLINE | ID: mdl-22564554

ABSTRACT

BACKGROUND: A(H1N1)v2009 influenza vaccination of pregnant women was a challenge for health care providers, as little safety data were available. METHODS: We prospectively followed the pregnancies of women who were vaccinated at any time during pregnancy or ≤ 4 weeks prior to conception and compared these outcomes to a control cohort matched by the estimated date of birth. Primary endpoints: rate of spontaneous abortion and major malformations. Secondary endpoints: preeclampsia, gestational age at birth, and birth weight. RESULTS: Pregnancy outcome of 323 women immunized with adjuvanted or non-adjuvanted A(H1N1)v2009 influenza vaccines from 2009-09-28 to 2010-03-31 were compared to 1329 control subjects. The risk for spontaneous abortions (HR 0.89; 95% CI 0.36-2.19) and the rate of major malformations (all trimesters: OR 0.87; 95% CI 0.38-1.77; preconception and first trimester exposure: OR 0.79; 95% CI 0.13-2.64) did not vary between the two cohorts. Furthermore, there was no increase in preeclampsia, prematurity, and intrauterine growth retardation in the vaccinated cohort. CONCLUSION: The results of our study do not indicate a risk for the pregnant woman and the developing embryo/fetus after H1N1 vaccination. We provide and apply methods novel in observational studies on pregnancy outcome, especially if a single dose exposure is investigated.


Subject(s)
Influenza Vaccines/adverse effects , Pregnancy Outcome , Vaccination/adverse effects , Adolescent , Adult , Case-Control Studies , Female , Humans , Influenza A Virus, H1N1 Subtype , Middle Aged , Pregnancy , Prospective Studies , Risk Factors , Young Adult
5.
Mol Cancer Ther ; 10(1): 186-97, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21220501

ABSTRACT

Lysophosphatidylcholine (LysoPC) is an important intermediate in degradation and biosynthesis of phosphatidylcholine (PC). Reduced plasma LysoPC levels observed in patients with advanced cancer indicate a deregulation of LysoPC metabolism in metastasis. Recent data showed strong antimetastatic effects of liposomes consisting of saturated PC in a murine pancreatic metastasis model. LysoPC, generated from saturated PC after accumulation of the liposomes in tumor tissue, might be contributing to these effects. Examining effects of high local concentrations of saturated LysoPC and investigating potential molecular mechanisms, fast removal of saturated LysoPC from medium by murine B16.F10 melanoma cells and radical shifts in tumor cell membrane fatty acid (FA) composition toward saturated FAs were observed in vitro. Scanning electron microscopy revealed remarkable morphologic surface changes of LysoPC-treated tumor cells, probably causing their impaired migratory ability on fibronectin. A LysoPC concentration exceeding a threshold of about 400 µmol/L, slightly above physiologic levels, strongly reduced VLA-4-mediated binding of B16.F10 cells to VCAM-1 as well as P-selectin-dependent interaction with activated platelets, although expression levels were not altered. These findings were reflected in a syngenic intravenous lung invasion model using repeatedly ex vivo LysoPC-treated (450 µmol/L) B16.F10 cells, resulting in significantly reduced lung metastasis-like lesions (-48.3%, P = 0.006). Prior application of 50 IU unfractionated heparin further reduced lung invasion (-81.6%, P = 0.043). Our work shows for the first time that saturated LysoPC in high concentrations reduces melanoma cell adhesion in vitro and hematogeneous dissemination in vivo by direct ex vivo tumor cell targeting.


Subject(s)
Integrin alpha4beta1/metabolism , Lung Neoplasms/prevention & control , Lung Neoplasms/secondary , Lysophosphatidylcholines/pharmacology , Melanoma, Experimental/drug therapy , Melanoma, Experimental/secondary , P-Selectin/metabolism , Animals , Cell Adhesion/drug effects , Cell Membrane/drug effects , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Male , Melanoma, Experimental/metabolism , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , P-Selectin/pharmacology , Recombinant Proteins/pharmacology
6.
Thromb Haemost ; 102(5): 816-22, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19888514

ABSTRACT

Heparin possesses antimetastatic effects that were related to various molecular mechanisms beyond anticoagulant activities. The ability of heparin to interfere with the function of adhesion receptors in the metastatic course appears as a promising therapeutic approach. This refers to numerous findings that heparin attenuates metastasis in a selectin-dependent manner. We recently demonstrated that heparin interferes with the integrin VLA-4 on murine melanoma cells binding to VCAM-1. To confirm this activity and to obtain further insight into molecular recognition of heparin by VLA-4, we investigated the inhibition of VLA-4 mediated binding of human melanoma MV3 cells to immobilised VCAM-1 by different heparins. The size of heparin has an important impact on inhibition. Unfractionated heparin (UFH) and tinzaparin, a low-molecular-weight heparin (LMWH) representing a mean of about 18-20 monomers, displayed high inhibitory activity. Fractionating tinzaparin to 14-18 monomers reduced inhibition slightly, while the pentasaccharide fondaparinux was without effects. To confirm molecular recognition of tinzaparin by VLA-4, a surface acoustic wave-biosensor was applied. A VLA-4 containing membrane preparation of MV3 cells was immobilised at the sensors to allow for detection of kinetic binding constants of tinzaparin compared to VCAM-1. Tinzaparin binds to VLA-4 with affinity in the low micromolar range (4.61 x 10(-6) M), which clearly indicates specific molecular recognition. Furthermore, tinzaparin displays a nearly identical k(off) compared to VCAM-1 (5.13 x 10(-3) s(-1) versus 3.44 x 10(-3) s(-1)) which is evident for interference with the ligand binding. The data provide evidence for a direct confirmation of heparin binding to VLA-4 and thus, contribute to understand the antimetastatic activity of heparin.


Subject(s)
Cell Adhesion/drug effects , Heparin, Low-Molecular-Weight/pharmacology , Heparin/metabolism , Integrin alpha4beta1/metabolism , Melanoma/pathology , Acoustics , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal, Humanized , Biosensing Techniques , Cell Line/drug effects , Cell Line, Tumor/cytology , Cell Line, Tumor/drug effects , Drug Screening Assays, Antitumor , Endothelial Cells/cytology , Endothelial Cells/drug effects , Fondaparinux , Heparin/pharmacology , Heparin, Low-Molecular-Weight/chemistry , Humans , In Vitro Techniques , Integrin alpha4beta1/drug effects , Natalizumab , Neoplasm Metastasis , P-Selectin/antagonists & inhibitors , Polysaccharides/pharmacology , Recombinant Fusion Proteins/metabolism , Rheology , Tinzaparin , Tumor Necrosis Factor-alpha/pharmacology , Vascular Cell Adhesion Molecule-1/chemistry , Vascular Cell Adhesion Molecule-1/metabolism
7.
J Invest Dermatol ; 129(5): 1192-202, 2009 May.
Article in English | MEDLINE | ID: mdl-19052560

ABSTRACT

Leukocyte extravasation is initiated by an interaction of selectin adhesion molecules and appropriate carbohydrate ligands. Targeting those interactions seems a promising approach to treat chronic inflammation. We developed a beta-1, 3-glucan sulfate (PS3) with inhibitory activity toward L and P-selectins under static conditions. Here, detailed investigation showed inhibition of P- and L-selectins, but not E-selectin under flow conditions (relative reduction of interaction with appropriate ligands to 34.4+/-16.6, 8.5+/-3.6, or 99.5+/-9.9%, respectively, by PS3 for P-, L- or E-selectin). Intravital microscopy revealed reduction of leukocyte rolling in skin microvasculature from 22.7+/-5.0 to 12.6+/-4.0% after injection of PS3. In the next experiments, mice were sensitized with 2,4,-dinitrofluorobenzene (DNFB), and lymphocytes were transferred into syngeneic recipients, which were challenged by DNFB. Inflammatory responses were reduced when immunity was generated in mice treated with PS3 or in L-selectin-deficient mice. No effect was observed when L-selectin-deficient donor mice were treated with PS3, further suggesting that PS3 acted primarily through inhibition of L-selectin. Elicitation of a contact hypersensitivity response was reduced in P-selectin-deficient and in PS3-treated mice. Again, PS3 had no effect in P-selectin-deficient mice. PS3 is a potent P- and L-selectin inhibitor that may add to the therapy of inflammatory diseases.


Subject(s)
Dermatitis, Contact/drug therapy , Dermatitis, Contact/immunology , Glucans/pharmacology , L-Selectin/drug effects , P-Selectin/drug effects , Adoptive Transfer , Allergens/immunology , Allergens/pharmacology , Animals , Cell Communication/drug effects , Cells, Cultured , Dermatitis, Contact/metabolism , Dinitrofluorobenzene/immunology , Dinitrofluorobenzene/pharmacology , Disease Models, Animal , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Glucans/therapeutic use , Humans , L-Selectin/metabolism , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Male , Mice , Mice, Inbred C57BL , P-Selectin/metabolism , beta-Glucans/pharmacology , beta-Glucans/therapeutic use
8.
Phys Chem Chem Phys ; 10(15): 2078-88, 2008 Apr 21.
Article in English | MEDLINE | ID: mdl-18688362

ABSTRACT

The pure rotational spectra of 41 isotopic species of PbSe and PbTe have been measured in their X 1Sigma+ electronic state with a resonator pulsed-jet Fourier transform microwave spectrometer. The molecules were prepared by laser ablation of suitable target rods and stabilised in supersonic jets of noble gas. Global multi-isotopologue analyses yielded spectroscopic Dunham parameters Y01, Y11, Y21, Y31, Y02, and Y12 for both species, as well as effective Born-Oppenheimer breakdown (BOB) coefficients delta01 for Pb, Se and Te. Unusual large values of the BOB parameters for Pb have been rationalized in terms of finite nuclear size (field shift) effect. A direct fit of the same data sets to an appropriate radial Hamiltonian yielded analytic potential energy functions and BOB radial functions for the X 1Sigma+ electronic state of both PbSe and PbTe. Additionally, the magnetic hyperfine interactions produced by the uneven mass number A nuclei 207Pb, 77Se, 123Te, and 125Te were observed, yielding first determinations of the corresponding nuclear spin-rotation coupling constants.

9.
Thromb Haemost ; 100(6): 1166-75, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19132244

ABSTRACT

The clinical benefit of heparin in cancer patients to prolong survival can be attributed to non-anticoagulant mechanisms. Since adhesion molecules are crucially involved in tumour cell metastasis, their inhibition offers an attractive approach for interfering with the metastatic cascade. Heparin is known to attenuate metastasis in a selectin-dependent manner and possesses a variety of additional effects that are thought to influence tumour cell dissemination, proliferation, and angiogenesis. We investigated the adhesion behaviour of B16F10 melanoma cells in vitro regarding selectin- and VLA-4/VCAM-1-mediated binding to get an insight into underlying mechanisms of melanoma cell metastasis. We show that B16F10 cells display binding ability to P- and L-selectin as well as to isolated platelets. In contrast, B16F10 cells did not adhere to immobilized P-selectin under flow. This contributes to recent findings that elucidate a major role of platelet P-selectin for microemboli formation and thus, facilitating metastasis. In contrast, B16F10 cells adhered to endothelial cells under flow, which could partly be inhibited by a function-blocking anti-VCAM-1 mAb. To emphasize VCAM-1 function, we analyzed cell adhesion at immobilized VCAM-1 and observed an integrin dependency. Inhibition experiments reveal that heparin influences VLA-4-mediated binding pathways. By a combination of different techniques we prove that the site of heparin action is rather VLA-4 than VCAM-1. To our knowledge, this is the first time that heparin is shown to interfere with the VLA-4/VCAM-1 interaction leading to the suggestion of a novel heparin target. Our results may contribute to the understanding of how heparin exerts its anti-metastatic activity.


Subject(s)
Antineoplastic Agents/pharmacology , Cell Adhesion/drug effects , Heparin, Low-Molecular-Weight/pharmacology , Heparin/pharmacology , Integrin alpha4beta1/antagonists & inhibitors , Melanoma, Experimental/pathology , Animals , Blood Platelets/immunology , Cell Line, Tumor , Endothelial Cells/immunology , Humans , Integrin alpha4beta1/metabolism , L-Selectin/metabolism , Melanoma, Experimental/immunology , Mice , Neoplasm Metastasis , P-Selectin/metabolism , Stress, Mechanical , Time Factors , U937 Cells , Vascular Cell Adhesion Molecule-1/metabolism
10.
Biochemistry ; 46(20): 6156-64, 2007 May 22.
Article in English | MEDLINE | ID: mdl-17458940

ABSTRACT

P-Selectin, expressed on activated endothelial cells and platelets, is a high kinetic adhesion receptor involved in leukocyte rolling of the inflammatory response, or in tumor cell binding in the course of metastasis. Thus, P-selectin inhibition is a promising therapeutic target. The anti-inflammatory and anti-metastatic activities of heparin have partly been related to the inhibition of P-selectin binding. Here we apply a quartz crystal microbalance (QCM) biosensor to determine the kinetic constants of heparin and other sulfated polysaccharides binding to immobilized P-selectin. Binding kinetics of the derivatives were correlated with their inhibitory capacity in a P-selectin cell rolling assay. Three commercial heparins differ in cell rolling inhibition and display slightly different affinities (KD 1.21 x 10(-6) M to 5.86 x 10(-7) M). Inhibitory capacity appears to be mainly driven by a slow off-rate from the receptor (2.27 x 10(-3) s-1 to 1.23 x 10(-3) s-1). To correlate the impact of binding kinetics on inhibitory capacity structurally, we analyzed six semisynthetic glucan sulfates. They display different degrees of sulfation (DS), which has a strong influence on inhibitory activity. Kinetic data illustrate that the inhibitory capacity correlates excellently with the off-rate of these polysaccharides (R = 0.99), while the association (on-rate) affects activity to a lesser extent. In general, the consideration of binding kinetics sheds new light on the mechanism of selectin inhibition. A much slower dissociation of the inhibitors from the receptor than the physiological ligands is key for inhibitory capacity. Structurally, highly charged compounds with a slow off-rate, such as heparin or glucan sulfates, appear as potent candidates for P-selectin inhibition.


Subject(s)
Cell Migration Inhibition , Glucans/chemistry , Glucans/metabolism , Heparin/analogs & derivatives , P-Selectin/metabolism , Proteoglycans/chemistry , Proteoglycans/metabolism , Binding Sites , Biosensing Techniques , Cell Adhesion/physiology , Cell Movement/physiology , Heparin/chemistry , Heparin/metabolism , Humans , Kinetics , Ligands , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/genetics , Membrane Glycoproteins/metabolism , P-Selectin/physiology , Protein Binding , Quartz/chemistry , Quartz/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , U937 Cells
11.
Biochem Pharmacol ; 72(4): 474-85, 2006 Aug 14.
Article in English | MEDLINE | ID: mdl-16780802

ABSTRACT

Selectin-mediated leukocyte rolling along the endothelium is of key importance for maintaining the cellular immune response. The anti-inflammatory activities of heparin have partly been related to inhibition of P-selectin binding. Heparin, however, suffers from its heterogeneous variable structure, the animal origin and multiple in vivo effects. As P-selectin is a promising target for anti-inflammatory approaches, we focused on P-selectin inhibition by other sulfated polysaccharides and compared them with six heparins. We examined 15 structurally defined semisynthetic sulfated glucans, non-animal-derived from the linear glucans phycarin, curdlan or pullulan. The derivatives gradually differ in their degree of sulfation, molecular weight, and glycosidic linkage. The inhibitory capacity was analysed in a parallel plate flow chamber, detecting the rolling of U937 cells on P-selectin layers. Unfractionated heparins displayed variabilities between different preparations. Considering fractionated heparins, exceeding of a minimal mass is essential for activity. Comparing the glucan sulfates, charge density is the most important parameter for P-selectin binding. Highly sulfated derivatives are excellent inhibitors, the reduced cell binding up to 16.2+/-6.4% strongly exceeded the heparin activities. Molecular weight is of minor effects, while glycosidic backbone linkage holds certain importance. To check the P-selectin inhibition in vivo, heparin and one phycarin sulfate were tested using intravital microscopy of microvasculature in mice. Both compounds significantly reduced the rolling fractions of activated platelets on endothelium as effective as a blocking P-selectin antibody. Our study indicates that semisynthetic glucan sulfates with optimal structures block P-selectin excellently and might become promising candidates for anti-inflammatory drugs to replace heparin for certain applications.


Subject(s)
P-Selectin/pharmacology , Polysaccharides/pharmacology , Animals , Antibodies, Monoclonal/pharmacology , Anticoagulants/chemistry , Anticoagulants/pharmacology , Blood Platelets/physiology , Cell Adhesion/drug effects , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Glucans/chemistry , Glucans/pharmacology , Heparin/chemistry , Heparin/pharmacology , Humans , Leukocyte Rolling/drug effects , Mice , Mice, Inbred C57BL , Molecular Structure , P-Selectin/immunology , P-Selectin/physiology , Platelet Activation/drug effects , Polysaccharides/chemistry , Structure-Activity Relationship , Sulfates/chemistry , U937 Cells , beta-Glucans/chemistry , beta-Glucans/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...